Neulasta® is indicated to decrease the incidence of infection,
as manifested by febrile neutropenia, in patients with nonmyeloid malignancies
receiving myelosuppressive anticancer drugs associated with a clinically significant
incidence of febrile neutropenia.
Neulasta® (pegfilgrastim) is indicated to decrease the incidence
of infection, as manifested by febrile neutropenia, in patients with nonmyeloid
malignancies receiving myelosuppressive anticancer drugs associated with a clinically
significant incidence of febrile neutropenia.
